个人简介

齐明，男，博士。2018年毕业于暨南大学药学专业，获学士学位。2023年毕业于暨南大学中药药理学专业，获博士学位（导师：张冬梅研究员、叶文才教授）。2023年进入暨南大学临床医学博士后流动站进行博士后研究。担任Technology in Cancer Research & Treatment期刊编委、Traditional Medicine Research和Asian Journal of Tranditional Medicines期刊青年编委、Biochemical Pharmacology和Heliyon等期刊审稿人。

一直从事周细胞介导肿瘤耐药和转移的作用机制研究。于J Clin Invest、Signat Transduct Target Ther、Drug Resist Updat、J Extracell Vesicles、Acta Pharm Sin B等SCI期刊发表论文18篇，其中第一（含共同）作者论文7篇；ResearchGate显示总引用次数约460次，h-index为10。申请中国发明专利1项。已获国家资助博士后研究人员计划B档资助，主持中国博士后面上资助1项。在读期间曾获研究生国家奖学金、广东省“互联网+”大学生创新创业大赛铜奖（2次）、广东省研究生学术论坛-药学分论坛口头汇报一等奖（2次）、暨南大学生命科学创新奖、暨南大学优秀毕业研究生等奖励。

 研究方向

周细胞介导肿瘤耐药和转移的作用机制研究以及创新药物的研究开发。

代表性论文

1.Qi M#, Fan S#, Huang M#, Pan J, Li Y, Miao Q, Lyu W, Li X, Deng L, Qiu S, Liu T, Deng W, Chu X, Jiang C, He W, Xia L, Yang Y, Hong J, Qi Q, Yin W, Liu X, Shi C, Chen M*, Ye W*, Zhang D*. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to anti-angiogenics in colorectal cancer liver metastasis models. The Journal of Clinical Investigation, 2022, 132(19): e157399. (IF: 15.9)

2.Fan SR#, Qi M#, Qi Q#, Miao Q, Deng LJ, Pan JH, Qiu SH, He JS, Huang MH, Li XB, Huang J, Lin JP, Lyu WY, Deng WQ, He YY, Liu XS, Gao LF, Zhang DM*, Ye WC*, Chen MF*. Targeting FAPα--positive lymph node metastatic tumor cells suppresses colorectal cancer metastasis. Acta Pharmaceutica Sinica B, 2024 Feb;14(2):682-697. (IF: 14.5)

3.Huang MH#, Qi M#, Yang HY#, Peng Z, Chen SG, Liang MC, Hu YZ, Deng LJ*, Hu M*. Noninvasive strategies for the treatment of tiny liver cancer: integrating photothermal therapy and multimodality imaging EpCAM-guided nanoparticles. ACS Applied Materials & Interfaces, 2023, 15(18):21843-21853. (IF: 9.5) 

4.Zhu SL#, Qi M#, Chen MT#, Lin JP, Huang HF, Deng LJ*, Zhou XW*. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer. Phytomedicine. 2024 Jan 19;128:155377. (IF: 24.3)

5.Deng LJ#, Qi M#, Peng QL, Chen MF, Qi Q, Zhang JY, Yao N, Huang MH, Li XB, Peng YH, Liu JS, Fu DR, Chen JX, Ye WC*, Zhang DM*. Arenobufagin induces MCF-7 cell apoptosis by promoting JNK-mediated multisite phosphorylation of Yes-associated protein. Cancer Cell International, 2018, 18:209. (IF: 5.8) 

6.Deng LJ#, Qi M#, Li N#, Lei YH, Zhang DM, Chen JX*. Natural products and their derivatives: promising modulators of tumor immunotherapy. Journal of Leukocyte Biology, 2020, 108(2): 493-508. (IF: 5.5)

7.Gan H#, Qi M#, Chan C#, Leung P, Ye GN, Lei YH, Liu AA, Xue FF, Liu DD, Ye WC, Zhang DM, Deng LJ*, Chen JX*. Digitoxin inhibits HeLa cell growth through the induction of G2/M cell cycle arrest and apoptosis in vitro and in vivo. International Journal of Oncology, 2020, 57(2): 562-573. (IF: 5.2) 

8.Huang MH#, Chen MF#, Qi M, Ye GN, Pan JH, Shi CZ, Yang YL, Zhao LY, Mo XK, Zhang YR, Li Y, Zhong JC, Lu WJ, Li XB, Zhang JY, Lin JR, Luo LP, Liu TZ, Patrick MK Tang, Hong A, Cao YH*, Ye WC*, Zhang DM*. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. Journal of Extracellular Vesicles, 2021;10:e12096. (IF: 16.0)

9.Deng LJ#, Deng WQ#, Fan SR#, Chen MF, Qi M, Lyu WY, Qi Q, Tiwari AK. Chen JX*, Zhang DM*, Chen ZS*. m6A modification: recent advances, anticancer targeted drug discovery and beyond. Molecular Cancer, 2022, 21(1):52. (IF: 37.3)

10.Wen Q#, Huang MH#, Xie JW#, Liu RY#, Miao Q, Huang JJ, Zhang JQ, lyu WY, Qi M, Wu CY, Qi Q, Zhang ZJ, Deng R, Wang CR, Chen ZS, Zhang DM*, Ye WC*, Chen MF*. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resistance Updates, 2023, 69: 100975. (IF: 24.3)